Bone marrow reconstitution with normal autologous cells demonstrated by VNTR analysis after allogeneic bone marrow transplantation for chronic myelogenous leukemia

TO THE EDITOR
Allogeneic stem cell transplantation is the only presently available procedure for a potentially successful cure of chronic myeloid leukemia (CML) by which the patient's hematopoietic cells are replaced by those derived from donor stem cells. 1, 2 Following BMT, engraftment, remission or relapse must be monitored by identifying the origin of cell populations 3 and the presence of residual Ph + clones or other cytogenetic rearrangements. 4, 5 In July 1990, a 23-year-old male with Ph + CML received a BMT from his HLA-identical brother at the British Hospital (Montevideo, Uruguay). At that time, the patient was in second chronic phase after alpha-interferon and hydroxyurea treatment, and he had an Hb of 8.06 mmol/l, WBC 6 × 10 9 /l and platelet count of 400 × 10 9 /l. His bone marrow aspirate showed a normal myeloid sector, while cytogenetic analysis demonstrated 10/20 46,XY, Ph + , t(3;21) and 10/20 46,XY cells. Molecular analysis by Southern blotting and hybridization with a 3Ј bcr probe (1.2 kb HindIII/BglII fragment) confirmed the presence of a rearrangement within the M-BCR (major break-point cluster region) (Figure 1) . 6 Pre-BMT conditioning regimen was high-dose cyclophosphamide (50 mg/kg/per day for 2 days) and busulphan (4 mg/kg/per day for 4 days). GVHD prophylaxis was cyclosporin A at a dose of 10 mg/kg from day +1 to day +100. The number of non-Tdepleted nucleated cells infused was 2.5 × 10 8 cells/kg. CFU-GM and CD34
+ cell quantification was not performed. Bone marrow repopulation was confirmed on day +14 with a WBC count of 0.5 × 10 9 /l and platelet count of 10 × 10 9 /l. Platelet count reached 20 × 10 9 /l on day +16, and 50 × 10 9 /l on day +19. Last platelet and red cell transfusions were done on day +17. No CSF stimulation was used. For a short period at that time the patient developed acute GVHD grade I associated with fever.
Two months after BMT, cytogenetic and Southern blot analyses were performed and subsequently repeated every 6 months. In all these instances bone marrow cells exhibited a normal karyotype. Conversely, molecular analysis showed a BCR-ABL + profile 2 months after BMT while, on subsequent analyses, molecular remission was observed in coincidence with cytogenetic findings. Furthermore, after a 6 year followup period, the patient was clinically normal, with an Hbg of 7.44 mmol/l, WBC of 4.5 × 10 9 /l consisting of 65% neutrophils, 2% eosinophils, 0% basophils, 7% monocytes, 26% lymphocytes, and a platelet count of 300 × 10 9 /l. Moreover, cytogenetic and molecular analyses showed a normal karyotype (20/20 46,XY) and absence of a BCR-ABL rearrangement by Southern blot.
Since the origin of the hematopoietic cells that reconstituted his bone marrow could not be determined by karyotyping we assayed bone marrow DNA with the highly polymorphic VNTR (variable number tandem repeat) probe, pYNZ22 (1.7 kb BamHI fragment), which allows individual-specific identification.
7 Surprisingly, this analysis showed only autologous cells because the observed pattern coincided exactly with the one obtained before BMT (Figure 2) . No donor's cells were demonstrated with this method (with regard to sensitivity our data indicate that a mixture of donor and recipient DNAs can be detected by Southern blot even when the minor population is only about 5-10% of total cells). This finding, taken together with the evidence of complete remission at the clinical, cytogenetic, and molecular levels would suggest that bone marrow reconstitution may have occurred from a pool of residual, normal hematopoietic cells, that survived the conditioning regimen, and that permanent engraftment did not occur. This unusual finding might have resulted from a successful elimination of leukemic clones and by positive selection of normal hemopoietic cells during pre-BMT treatment as well as a graft-versus-leukemia effect after transplantation. Presumably, a critical mass of normal cells must have remained to account for their capacity to reconstitute the patient's bone marrow. The detection of a BCR-ABL + profile 2 months after BMT can be explained by the presence of surviving leukemic cells with a limited proliferation capacity. This fact, added to unknown microenvironmental effects related to BMT, probably accounted for the proliferative advantage of normal cells.
Endogenous bone marrow reconstitution has been shown to result usually from proliferation of leukemic clones. [8] [9] [10] Transient recovery of host-derived hemopoiesis after allogeneic BMT without detectable leukemia relapse has been shown previously. 11 However, an unusual case of durable and normal autologous repopulation was reported by Wakui et al. 12 The detection of a similar case but using an individualspecific molecular marker, such as the pYNZ22 probe is reported here. These findings indicate that molecular analyses of CML patients submitted to BMT should not be limited to detection of BCR-ABL rearrangements but should also include similar assessments for monitoring engraftment and reconstitution with VNTR probes during successive follow-ups.
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